How much does Hansizhuang (Serplulimab Injection) Cost& price without insurance in China?

Hansizhuang® is the commercial brand name of Serplulimab Injection, a recombinant humanized anti-programmed death 1 (anti-PD-1) monoclonal antibody developed by Henlius Biotech. It binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2, thereby restoring the immune system’s anti-tumor activity.

Main Indications
First-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy.
Treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Treatment of unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy.
Treatment of unresectable recurrent or metastatic microsatellite instability-high (MSI-H) solid tumors.

Common Side Effects
Common mild adverse reactions: Fatigue, fever, rash, pruritus, diarrhea, and nausea.
Laboratory abnormalities: Decreased lymphocyte count, decreased neutrophil count, and elevated liver enzymes.
Severe but uncommon risks: Immune-related adverse events (including pneumonitis, colitis, hepatitis, endocrinopathies), severe infections, and infusion reactions.

Approval Status in China
Hansizhuang® (Serplulimab Injection, 100mg/10mL) was officially approved for marketing in China in 2022. It is currently a prescription anti-tumor drug included in China’s National Medical Insurance List.

Buy Hansizhuang (Serplulimab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.